This means that EpCAM-specific antibodies are conjugated with cytotoxic agents, such as doxorubicin, paclitaxel, calicheamicin, topoisomerase I inhibitors, alpha amanitin, and indolinobenzodiazepine pseudodimers (IGNs), to specifically kill the EpCAM+ tumor cells
This directly and significantly lowers the production of pro-inflammatory cytokines like Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF-), effectively cooling the systemic inflammatory fire that drives chronic illness symptoms
A Spreading Patchwork of No CVS Caremark, the nations largest PBM, removed Zepbound from its standard formularies on July 1, 2025
Given the volume of compounded GLP1 products being marketed directly to consumers and associated safety concerns, it makes sense that FDA is unlikely to deprioritize the issue
J Neurosci 32: 4812-4820
Peptide Therapies for Cartilage Repair and Inflammation Management